Earnings Releases·Nov 3, 2026, 4:36 PM ET

Ceribell — Q3 2026 Earnings Summary

Total revenue grew 30% year-over-year to $29.3 million, driven by 31% growth in product sales and 28% growth in subscriptions, while gross margin expanded to 90% from 88% in the prior year period.
The company raised full-year 2026 revenue guidance to $115 million–$117 million, reflecting 29%–31% projected growth over 2025, while net loss widened to $21.4 million due to increased operating expenses.
Strategic milestones include the full commercial launch of the delirium monitoring solution, FDA 510(k) clearance for quantitative EEG trending, and the addition of 35 net new customers to reach 747 total active accounts.
Management anticipates a pivotal 2027 driven by a new hardware platform and delirium solution, supported by a new $60 million credit facility and manufacturing cost reductions from its Vietnam line.